| Ytd | 119.36% | |
| 1y | 217.25% |
| Open | 25.81 | Prev Close | 24.15 | Low | 23.92 | High | 25.96 | Mkt Cap | 245.61M |
| Vol | 167.38K | Avg Vol | 357.01K | EPS | -15.07 | P/E | -1.68 | Forward P/E | -0.63 |
| Beta | 1.55 | Short Ratio | 2.47 | Inst. Own | 77.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 27.52 | 200-d Avg | 20.80 | 1yr Est | 11.50 |
STRO News
Wall Street analysts reshuffled their ratings on Friday with some bold calls that could move money f
Affinity Asset Advisors LLC grew its holdings in shares of Sutro Biopharma, Inc. (NASDAQ: STRO) by 4
Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial
Analysts change outlook on top Wall Street names. Piper Sandler cuts target for Figma to $30, Roth C
– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STR
Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading se
STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid t
Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report)'s stock price traded up 10.4% on Friday after
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume.
– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC;
Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given an average recommendation of "
Sutro Biopharma is an early-stage ADC developer, trading at a $406m market cap after a strong 6-mont
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the C
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume.
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the C
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume.
Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given a consensus recommendation of
Shares of Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) have received a consensus recommend
Sutro Biopharma, Inc. ( STRO ) Discusses Strategic Reset and Progress in Next-Generation ADC Pipelin
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.67 per share versus the Zacks Cons
– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, i
On Friday, 1043 companies hit new 52-week lows.